Authors:
Address: Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, FL 32610-0496, USA. tkauf@ufl.edu
Journal:

Publication:

abstract

OBJECTIVE:

Existing estimates of human immunodeficiency virus (HIV)-related health state utilities are inadequate for comparing alternative treatments on the basis of regimen-specific attributes such as dosing requirements or tolerability. The objective of this study was to examine the marginal impact of dosing, adverse events (AEs), and other factors on patients' health state utilities.

METHODS:

Treatment naive and experienced HIV patients participating in five open-label trials of highly active antiretroviral therapy (HAART) completed the 36-Item Short Form Health Survey (SF-36) instrument at various time points. SF-36 responses were converted to utilities using a previously reported algorithm. Expected utilities were estimated as a function of patient demographics, regimen attributes, disease status, and AEs using a mixed-effects maximum likelihood model. Mean utilities for five HIV health states were derived from predicted patient utilities.

RESULTS:

Negative predictors of utility included greater age (-0.001), prior acquired immune deficiency syndrome-defining events (-0.036), female gender (-0.038), and injection drug use (-0.056; P < 0.01 for all). Utility also depended on CD4+ cell count (P < 0.01), but not the presence of undetectable viral load. Regimen attributes were marginally associated with changes in utility. Depression was associated with the largest decrease in utility (-0.054, P < 0.001) among the AEs examined. Using the model to generate predicted utilities from the sample provided mean estimates ranging from 0.742 (SD 0.058) to 0.798 (0.052) for CD4+ counts between 0 and 99 and > or =500 cells/mm(3), respectively.

CONCLUSIONS:

HIV patients' health-related quality of life may be substantially affected by clinically relevant patient-, disease-, and treatment-related factors, such as injection drug use, disease status, food/drink restrictions, and AEs.

Related Articles
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.
Med Decis Making. 2002
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS.
Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Med Decis Making. 2002 Jan-Feb; 22(1):27-38.
Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.
J Acquir Immune Defic Syndr. 2...
Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.
Stone VE, Jordan J, Tolson J, Miller R, Pilon T. J Acquir Immune Defic Syndr. 2004 Jul 1; 36(3):808-16.
The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy.
Ophthalmology. 2003
The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy.
Kempen JH, Martin BK, Wu AW, Barron B, Thorne JE, Jabs DA, Studies of Ocular Complications of AIDS Researh Group. Ophthalmology. 2003 May; 110(5):987-95.
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Enferm Infecc Microbiol Clin. ...
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin. 2009 Apr; 27(4):222-35. Epub 2009 Feb 26.
Review A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.
Pharmacoeconomics. 2006
Review A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.
Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. Pharmacoeconomics. 2006; 24(8):751-65.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster